Search research articles
Contact Us
Filters
Showing results (121-130 of 211) with videos related to
Page
of 22
Sort By:
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|
July 1, 1990
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors
O M El-Badry, C Minniti, E C Kohn, et al.
Endocrinology
|
February 1, 1996
Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor
V A Blakesley, T Kalebic, L J Helman, et al.
Cancer Research
|
September 15, 1990
Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors
P S Cohen, M J Cooper, L J Helman, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|
April 1, 1990
Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts
M J Cooper, G M Hutchins, P S Cohen, et al.
The Journal of Clinical Investigation
|
August 1, 1988
Chromogranin A expression in normal and malignant human tissues
L J Helman, A F Gazdar, J G Park, et al.
Pediatric Blood & Cancer
|
November 18, 2004
Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience
Paul C Nathan, Maria Tsokos, Lauren Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma
L J Helman, P S Cohen, S D Averbuch, et al.
Cancer Research
|
October 3, 2008
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
Liang Cao, Yunkai Yu, Isaac Darko, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 1, 1996
1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line
M C Velez-Yanguas, T Kalebic, M Maggi, et al.
Translational Oncology
|
November 12, 2016
The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma
Christine M Heske, Choh Yeung, Arnulfo Mendoza, et al.
Page
of 22
Search research articles
Search
Showing results (121-130 of 211) with videos related to
Sort By:
Page
of 22
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|
July 1, 1990
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors
O M El-Badry, C Minniti, E C Kohn, et al.
Endocrinology
|
February 1, 1996
Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor
V A Blakesley, T Kalebic, L J Helman, et al.
Cancer Research
|
September 15, 1990
Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors
P S Cohen, M J Cooper, L J Helman, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|
April 1, 1990
Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts
M J Cooper, G M Hutchins, P S Cohen, et al.
The Journal of Clinical Investigation
|
August 1, 1988
Chromogranin A expression in normal and malignant human tissues
L J Helman, A F Gazdar, J G Park, et al.
Pediatric Blood & Cancer
|
November 18, 2004
Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience
Paul C Nathan, Maria Tsokos, Lauren Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma
L J Helman, P S Cohen, S D Averbuch, et al.
Cancer Research
|
October 3, 2008
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
Liang Cao, Yunkai Yu, Isaac Darko, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 1, 1996
1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line
M C Velez-Yanguas, T Kalebic, M Maggi, et al.
Translational Oncology
|
November 12, 2016
The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma
Christine M Heske, Choh Yeung, Arnulfo Mendoza, et al.
Page
of 22